Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Skye Bioscience
(NASDAQ:SKYE)
Intraday
$12.75
0.02
[0.16%]
After-Hours
$12.75
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$12.75
0.02
[0.16%]
At close: May 8
$12.75
0
[0.00%]
After Hours: 8:52AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Skye Bioscience Stock (NASDAQ:SKYE)
Skye Bioscience Stock (NASDAQ: SKYE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, May 02, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
6 days ago
Friday, April 19, 2024
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Apr 19, 2024, 1:25PM
Friday, April 12, 2024
Oppenheimer Initiates Coverage On Skye Bioscience with Outperform Rating, Announces Price Target of $25
Benzinga Newsdesk
-
Apr 12, 2024, 5:27AM
Thursday, March 14, 2024
Piper Sandler Reiterates Overweight on Skye Bioscience, Raises Price Target to $20
Benzinga Newsdesk
-
Mar 14, 2024, 10:30AM
Monday, February 05, 2024
Skye Bioscience And 2 Other Penny Stocks Insiders Are Buying
Avi Kapoor
-
Feb 5, 2024, 9:30AM
Piper Sandler Initiates Coverage On Skye Bioscience with Overweight Rating, Announces Price Target of $12
Benzinga Newsdesk
-
Feb 5, 2024, 7:11AM
Wednesday, August 30, 2023
Skye Bioscience Board Member Awarded $23K Worth of Stock Options
Benzinga Insights
-
Aug 30, 2023, 11:00AM
Board Member at Skye Bioscience Acquires Company Stock Options Worth 1,472,692 Shares
Benzinga Insights
-
Aug 30, 2023, 11:00AM
Monday, August 28, 2023
13G Shows Versant Venture Capital III, L.P. 19.6% Stake In Skye Biosciences
Benzinga Newsdesk
-
Aug 28, 2023, 4:33PM
Friday, August 25, 2023
Cannabis Stock Gainers And Losers From August 25, 2023
Benzinga Insights
-
Aug 25, 2023, 5:30PM
Thursday, August 24, 2023
Cannabis Stock Gainers And Losers From August 24, 2023
Benzinga Insights
-
Aug 24, 2023, 5:30PM
Wednesday, August 23, 2023
Marijuana Stock Movers For August 23, 2023
Benzinga Insights
-
Aug 23, 2023, 5:30PM
Director of Skye Bioscience Makes $8.78M Buy
Benzinga Insights
-
Aug 23, 2023, 11:02AM
Tuesday, August 22, 2023
Marijuana Stock Movers For August 22, 2023
Benzinga Insights
-
Aug 22, 2023, 5:30PM
Monday, August 21, 2023
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Benzinga Insights
-
Aug 21, 2023, 5:30PM
Skye Secures $17M And Acquires Novel Phase 2-Ready Cannabinoid 1 Receptor Inhibitor
Vuk Zdinjak
-
Aug 21, 2023, 8:29AM
Friday, August 18, 2023
Cannabis Stock Movers For August 18, 2023
Benzinga Insights
-
Aug 18, 2023, 5:30PM
Thursday, August 17, 2023
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
Benzinga Insights
-
Aug 17, 2023, 5:30PM
Wednesday, August 16, 2023
Cannabis Stock Gainers And Losers From August 16, 2023
Benzinga Insights
-
Aug 16, 2023, 5:30PM
Monday, August 14, 2023
Cannabis Stock Gainers And Losers From August 14, 2023
Benzinga Insights
-
Aug 14, 2023, 5:30PM
Friday, August 11, 2023
Cannabis Stock Gainers And Losers From August 11, 2023
Benzinga Insights
-
Aug 11, 2023, 5:30PM
Tuesday, August 08, 2023
Marijuana Stock Movers For August 8, 2023
Benzinga Insights
-
Aug 8, 2023, 5:30PM
Monday, August 07, 2023
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
Benzinga Insights
-
Aug 7, 2023, 5:30PM
Wednesday, August 02, 2023
Marijuana Stock Movers For August 2, 2023
Benzinga Insights
-
Aug 2, 2023, 5:30PM
Tuesday, August 01, 2023
Marijuana Stock Movers For August 1, 2023
Benzinga Insights
-
Aug 1, 2023, 5:30PM
Monday, July 31, 2023
Marijuana Stock Movers For July 31, 2023
Benzinga Insights
-
Jul 31, 2023, 5:30PM
Friday, July 28, 2023
Cannabis Stock Gainers And Losers From July 28, 2023
Benzinga Insights
-
Jul 28, 2023, 5:30PM
Wednesday, July 26, 2023
Cannabis Stock Gainers And Losers From July 26, 2023
Benzinga Insights
-
Jul 26, 2023, 5:30PM
Monday, July 24, 2023
Cannabis Stock Movers For July 24, 2023
Benzinga Insights
-
Jul 24, 2023, 5:30PM
Friday, July 21, 2023
Cannabis Stock Movers For July 21, 2023
Benzinga Insights
-
Jul 21, 2023, 5:30PM
Thursday, July 20, 2023
Cannabis Stock Movers For July 20, 2023
Benzinga Insights
-
Jul 20, 2023, 5:30PM
Thursday, July 06, 2023
Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial
Vuk Zdinjak
-
Jul 6, 2023, 8:23AM
Wednesday, April 19, 2023
Short Volatility Alert: Skye Bioscience
Christopher Sappo
-
Apr 19, 2023, 9:26AM
Wednesday, March 15, 2023
Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma
Vuk Zdinjak
-
Mar 15, 2023, 9:04AM
Thursday, March 09, 2023
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
David Willey
-
Sponsored
Tuesday, March 07, 2023
Short Volatility Alert: Skye Bioscience
Christopher Sappo
-
Mar 7, 2023, 8:36AM
Friday, February 24, 2023
Skye Receives Positive Safety Review Of Cannabinoid Based Drug For Treatment Of Glaucoma After Second Cohort Of Phase 1 Study
Vuk Zdinjak
-
Feb 24, 2023, 10:37AM
Friday, January 27, 2023
Skye One Step Closer To Phase 2 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
Vuk Zdinjak
-
Jan 27, 2023, 7:54AM
Thursday, December 22, 2022
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
Ernest Dela Aglanu
-
Sponsored
Monday, December 19, 2022
Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down
Jelena Martinovic
-
Dec 19, 2022, 12:45PM
Friday, December 16, 2022
Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Bill Haddad
-
Dec 16, 2022, 7:07AM
Wednesday, November 16, 2022
Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
Vuk Zdinjak
-
Nov 16, 2022, 11:28AM
Tuesday, September 20, 2022
Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma
Vuk Zdinjak
-
Sep 20, 2022, 11:13AM
Monday, July 25, 2022
Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma
Mark Gilman
-
Sponsored
Thursday, July 21, 2022
Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer
Vuk Zdinjak
-
Jul 21, 2022, 8:41AM
Thursday, May 12, 2022
Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
Vuk Zdinjak
-
May 12, 2022, 12:17PM
Thursday, March 03, 2022
Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma
Nina Zdinjak
-
Mar 3, 2022, 10:14AM
Thursday, December 23, 2021
Cannabis Movers & Shakers: Skye Bioscience, The Flowr Corp, Charlotte's Web, Rapid Dose Therapeutics
Jelena Martinovic
-
Dec 23, 2021, 7:27AM
Tuesday, July 20, 2021
These OTC Securities Had the Most Trading Activity in June
Michael O'Connor
-
Sponsored
Thursday, July 08, 2021
Watch CV Sciences & Lyphe Group At The Benzinga Cannabis Hour
Jose Rodrigo Safdiye
-
Jul 8, 2021, 10:55PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
